Large eye-care hospital chain performing cataract surgery, LASIK and other ophthalmic procedures across India and Africa.
Large eye-care hospital chain performing cataract surgery, LASIK and other ophthalmic procedures across India and Africa.
Earns a fee per procedure from patients, who mostly pay themselves or through private insurance, with cataract surgery the largest line, and it runs centres across several tiers of Indian cities and in Africa. It has bought smaller eye hospitals to extend its network.
In one line: India's dedicated eye-care hospital chain, akin to a focused LASIK/cataract specialist net.
Moat: narrow (brand, scale, process know-how). Large-scale, standardized eye-care delivery model with a recognized brand built over decades.
Headquarters: Chennai, India · Founded: 1957 · Employees: 7,176
Size Dr. Agarwal's Health Care (AGARWALEYE.NS) is an India Health Care company (Medical/Nursing Services) with a market value of $1.86B, the 397th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹549.50 on 18 Nov 2026.
Performance Over six months the shares gained 20.3%, against +24.4% for the median peer and +3.8% for the India market (cap-weighted) — 10th lowest of 21 in its peer set.
Growth Revenue grew 25.9% over the last twelve months (peer median +7.9%); the operating margin is 14.6% (peer median 3.2%).
Valuation It trades at 77.1× forward earnings against a peer median of 31.7× (2nd most expensive of 17).
Price implies For today's price to make sense, revenue must grow about 43% a year for seven years (Req g). Recent delivered growth is +27%, so the hurdle is +16 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 4.6 points below its cost of capital (12.5% WACC).
Next results Next results expected around 12 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹23.6B | ₹20.8B | ₹17.1B | ₹13.3B | ₹10.2B |
| Revenue growth | — | +22% | +28% | +31% | — |
| Gross profit | ₹7.48B | ₹6.05B | ₹4.80B | ₹3.85B | ₹2.96B |
| EBITDA | ₹6.52B | ₹5.80B | ₹4.69B | ₹3.68B | ₹2.77B |
| Net income | ₹1.73B | ₹1.33B | ₹835M | ₹831M | ₹941M |
| Free cash flow | n/a | ₹684M | ₹196M | ₹876M | ₹497M |
| Capital expenditure | n/a | ₹4.61B | ₹3.21B | ₹2.32B | ₹1.58B |
| Total debt | ₹11.8B | ₹10.7B | ₹9.61B | ₹9.66B | ₹8.57B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Dr. Agarwal's Health Care AGARWALEYE.NS | $1.86B | +20% | +26% | 15% | 77.1× | 43.0% |
| Global Health MEDANTA.NS | $4.13B | +16% | +26% | 17% | 50.4× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | AGARWALEYE.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +17.3% | -0.3% | 4th highest of 21 |
| 6-month return | +20.3% | +24.4% | 10th lowest of 21 |
| Distance from 52-week high | -3.9% | -22.4% | 5th highest of 21 |
| Revenue growth (TTM) | +25.9% | +7.9% | 2nd highest of 21 |
| Operating margin | 14.6% | 3.2% | 2nd highest of 21 |
| Forward P/E | 77.1× | 31.7× | 2nd most expensive of 17 |
| Growth the price implies (Req g, 7 yrs) | 43.0% | 6.6% | most demanding of 15 |
| Growth delivered (Del g) | +26.9% | +8.1% | highest of 15 |
| Hurdle (Req g minus delivered) | +16.1 pp | +6.1 pp | 3rd most demanding of 15 |
| ROIC minus cost of capital | -4.6 pp | -4.1 pp | 9th lowest of 20 |
| EV / EBITDA | 28.3× | 12.1× | 4th most expensive of 14 |
| Net debt / EBITDA | 1.6× | 2.9× | 8th least indebted of 16 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Dr. Agarwal's Health Care AGARWALEYE.NS | India | $1.86B | +20% | +26% | 15% | 77.1× | 43.0% | +26.9% |
| Guangzhou Kingmed Diagnostics 603882.SS | China | $1.86B | +5% | -3% | 7% | 29.9× | 5.4% | -6.1% |
| Emeis EMEIS.PA | France | $1.78B | -33% | +4% | 3% | n/a | 21.2% | +8.5% |
| NeoGenomics NEO | United States | $1.98B | +72% | +11% | -6% | 53.5× | n/a | n/a |
| Azenta AZTA | United States | $2.03B | +162% | +5% | -2% | 83.2× | 38.0% | +3.9% |
| Dian Diagnostics 300244.SZ | China | $1.70B | +1% | -5% | 9% | 21.8× | 0.3% | -1.1% |
| Vijaya Diagnostic Centre VIJAYA.NS | India | $1.69B | +18% | +24% | 32% | 63.0× | 40.4% | +16.7% |
| AddLife ALIF-B.ST | Sweden | $2.13B | +15% | +2% | 8% | 39.0× | 21.1% | +14.6% |
| Personalis PSNL | United States | $1.62B | +88% | +17% | -157% | n/a | n/a | n/a |
| Sonida Senior Living SNDA | United States | $1.59B | -11% | +70% | -8% | n/a | n/a | n/a |
| Ambea AMBEA.ST | Sweden | $1.59B | +28% | +11% | 9% | 15.2× | 1.1% | +7.7% |
| GeneDx WGS | United States | $1.56B | +16% | +15% | -14% | 54.2× | n/a | n/a |
| Addus HomeCare ADUS | United States | $2.25B | +29% | +12% | 11% | 16.2× | 4.0% | +13.2% |
| agilon health AGL | United States | $1.52B | +12% | +2% | -2% | 34.1× | n/a | n/a |
| Teladoc Health TDOC | United States | $1.47B | +24% | -2% | -5% | n/a | -6.4% | +18.3% |
| Aveanna Healthcare AVAH | United States | $2.37B | +41% | +17% | 12% | 12.2× | 7.7% | +10.2% |
| Pediatrix Medical MD | United States | $2.41B | +37% | +2% | 12% | 12.4× | -4.4% | +2.0% |
| H.U.Group 4544.T | Japan | $1.44B | +24% | +1% | 3% | 39.9× | 9.7% | +2.1% |
| U.S. Physical Therapy USPH | United States | $1.42B | +53% | +10% | 10% | 29.4× | 18.8% | +13.0% |
| Ping An Healthcare and Technology 1833.HK | Hong Kong | $1.36B | -47% | +8% | 3% | 33.5× | 3.5% | -5.1% |
| Lumexa Imaging LMRI | United States | $1.35B | +89% | +8% | 2% | 16.0× | n/a | n/a |